Brendan Carroll, MD
Psychiatry · Fairborn, OHNPI 1861503591
Payments from drug & device makers
Across 993 payments — averaging $111.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$53K
- Alkermes, Inc.$23K
- AbbVie$13K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$9K
- Otsuka America Pharmaceutical, Inc.$2K
- Neurocrine Biosciences, Inc.$2K
- plus $8K from 21 others
What the payments were for
- Speaking & faculty fees$91,09082%
- Travel & lodging$1,2831%
- Food & beverage$18,68017%
- Education$1240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 83 | $53,244 |
| Alkermes, Inc. | 115 | $23,478 |
| AbbVie(2 entities) | 182 | $12,891 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 59 | $9,485 |
| Otsuka America Pharmaceutical, Inc. | 126 | $2,293 |
| Neurocrine Biosciences, Inc. | 80 | $1,845 |
| Almatica Pharma LLC | 18 | $1,787 |
| Vanda Pharmaceuticals Inc. | 42 | $831 |
| Johnson & Johnson | 55 | $757 |
| Sunovion Pharmaceuticals Inc. | 47 | $711 |
| Axsome Therapeutics, Inc. | 23 | $664 |
| Lundbeck LLC | 42 | $654 |
| Indivior Inc. | 39 | $633 |
| E.r. Squibb & Sons, L.L.C. | 16 | $619 |
| Avanir Pharmaceuticals, Inc. | 13 | $314 |
| Eisai Inc. | 13 | $200 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $164 |
| Supernus Pharmaceuticals, Inc. | 7 | $134 |
| Idorsia Pharmaceuticals US Inc | 1 | $96 |
| Biogen | 5 | $87 |
| Sage Therapeutics, LLC | 2 | $81 |
| Merck | 4 | $68 |
| Ironshore Pharmaceuticals Inc. | 2 | $42 |
| Noven Therapeutics, LLC | 3 | $39 |
| Shire North American Group Inc | 2 | $26 |
| Braeburn Inc. | 1 | $18 |
| Corium, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$74,524
- UZEDY$51,462
- VRAYLAR$10,581
- CAPLYTA$8,687
- ARISTADA$2,229
- LOREEV XR$1,419
- ARISTADA INITIO$557
- Auvelity$242
- ABILIFY MAINTENA$239
- COBENFY$239
- INGREZZA$229
- SPRAVATO$125
- NUEDEXTA$125
- Austedo XR$122
- ABILIFY ASIMTUFII$121
- Fanapt$113
- PERSERIS$107
How this compares
$111,177 in reported general payments places this provider in the 95th percentile of 1,119 psychiatry providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 12 | $79,361 |
| NuplazidPimavanserin Tartrate | 14 | $71,231 |
| VraylarCariprazine Hcl | 37 | $53,995 |
| Invega SustennaPaliperidone Palmitate | 21 | $46,269 |
| RexultiBrexpiprazole | 31 | $44,990 |
| Abilify MaintenaAripiprazole | 12 | $37,555 |
| Lurasidone Hcl | 30 | $23,482 |
| CaplytaLumateperone Tosylate | 13 | $22,201 |
| Aripiprazole | 52 | $7,782 |
| BelsomraSuvorexant | 12 | $5,080 |
| Clozapine | 29 | $3,277 |
| Quetiapine Fumarate | 91 | $3,126 |
| Olanzapine | 57 | $2,916 |
| Paliperidone ErPaliperidone | 21 | $2,833 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 65 | $2,281 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $2,293 | $82,54643 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $53,244 | $79,36112 claims |
| AbbVieVraylar | $12,891 | $53,99537 claims |
| Johnson & JohnsonInvega Sustenna | $757 | $46,26921 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $9,485 | $22,20113 claims |
| MerckBelsomra | $68 | $5,08012 claims |
| Almatica Pharma LLCSertraline Hcl | $1,787 | $53866 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,119 psychiatry providers in Ohio.
Other psychiatry in Fairborn
- Shishuka MalhotraCanton$15M
- Henry NasrallahCincinnati$3.8M
- Otto DuenoDayton$3.1M
- Diab AlmhanaAvon Lake$2.7M
- Mohamed Abdel AzizWest Chester$2.6M
- Fred RomeoColumbus$2.3M
- Mark WoyshvilleMiddleburg Heights$2.2M
- Amita PatelDayton$2.1M
- Caleb AdlerCincinnati$2M
- Richard SandersDayton$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.